THERAPY DOSSIER · th-9563929358fd

Cisatracurium (with pancuronium as a second neuromuscular blocking agent)

Drug · Muscle-type nicotinic acetylcholine receptor antagonist (ANTAGONIST; non-depolarizing; direct interaction)

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Muscle-type nicotinic acetylcholine receptor antagonist (ANTAGONIST; non-depolarizing; direct interaction)
Target: CHEMBL2362997
Injury models: Chemical/toxin
Reported indication: Non-depolarizing neuromuscular blocker: adjunct to general anesthesia, to facilitate tracheal intubation and provide skeletal muscle relaxation during surgery/mechanical ventilation; FDA-approved 1995 (Nimbex)
First approval: 1995
Development stage: Approved neuromuscular blocker; ARDS use off-label with mixed trial evidence (ACURASYS vs ROSE)
ChEMBL record: CHEMBL1201248 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Nimbex; Cisatracurium besylate; Cisatracurium besilate; 51W89
Note: Not recorded

Clinical trials 7

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT02404779 ↗Injury indicationPHASE4unknown

Cisatracurium vs placebo for intracranial hypertension in severe traumatic brain injury

Traumatic Brain Injury · Intracranial Hypertension

Enrolment: 34 · Results not recorded

NCT05624424 ↗PHASE4unknown

Remimazolam/propofol/sevoflurane sedation (cisatracurium co-administered)

Emergence Agitation · Anesthesia, General

Enrolment: 1317 · Results not recorded

NCT07185074 ↗PHASE4completed

Lidocaine aerosol with low-dose vs conventional-dose cisatracurium in ERCP

Intubation, Intratracheal

Enrolment: 186 · Results not recorded

NCT03337373 ↗PHASE4completed

PK/PD of a loading dose of cisatracurium in critically ill (ARDS) patients

Respiratory Distress Syndrome, Adult · ARDS, Human · Critical Illness

Enrolment: 10 · Results not recorded

NCT05736744 ↗PHASE2/PHASE3recruiting

Magnesium sulphate pretreatment on rocuronium vs cisatracurium block in pediatric surgery

Muscle Relaxation

Enrolment: 58 · Results not recorded

NCT02546843 ↗NAcompleted

Deep neuromuscular blockade during laparoscopic surgery in pediatric patients

Neuromuscular Blockade

Enrolment: 66 · Results not recorded

NCT02601508 ↗NAunknown

Surgical condition/complications with moderate vs deep NMB in laparoscopic gastrectomy

Neuromuscular Blockade

Enrolment: 80 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26540149 ↗2016Reported benefit

Neuromuscular Blocking Agent Cisatracurium Attenuates Lung Injury by Inhibition of Nicotinic Acetylcholine Receptor-alpha1.

RatChemical/toxinSprague-Dawleymalen = 10 rats per group across 4 groupsgiven during the 3 h of mechanical ventilation after acid instillation

Model: Acute lung injury by intratracheal instillation of hydrogen chloride followed by mechanical ventilation at tidal volume 6 mL/kg and PEEP 8 cm H2O for 3 h

Cisatracurium and pancuronium improved respiratory compliance and oxygenation and lowered plasma tumour necrosis factor alpha and interleukin 6 after acid-induced lung injury, with the anti-inflammatory effect reproduced by silencing nicotinic acetylcholine receptor alpha1 in human cells.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…